Cardiac involvement and myocardial inflammation are common in recovered COVID-19 patients, according to a new study published in JAMA Cardiology.

Hydroxychloroquine was once just an ordinary antimalarial medication—and then 2020 and COVID-19 happened. So how did we get here? 

Nearly 600 hospitals were considered for this updated ranking. 

The news comes just days after Major League Baseball began its pandemic-shortened season.

Consolidation has been a major theme for healthcare providers in recent years, with larger practices continuing to thrive compared to their smaller counterparts. But what about cardiology specifically? 

It’s been a long, hard battle for cardiologists, one full of change and uncertainty. But the situation is far from over.

The authors tracked more than 108,000 patients who suffered their first heart attack between 2009 and 2013.

Researchers tracked more than 302,000 patients with at least one cardiovascular risk factor.

Overall, the PCSK9 inhibitor was associated with a steady increase in coronary artery area and “significant coronary blood flow improvement.”

Researchers tracked data related to more than 178 million U.S. residents. Their findings could help with the development of public policies going forward.